郭瑞堂 柳玉美(通讯作者)
莱州市中医医院 全国基层名老中医工作室 山东烟台 261400
【摘要】目的:探讨分析癌性疼痛患者中利用针灸联合耳穴疗法的效果。方法:选取我院2020年1月至2021年1月癌性疼痛患者80例, 按照随机数字表法将换阵分为实验组与对照组,每组患者40例,两组患者施行药物治疗,实验组患者利用针灸联合耳穴疗法进行治疗,对照组患者仅使用常规三阶梯止疼药。对比两组患者止疼效果,评价患者生活质量和相关细胞状况。结果:实验组患者止疼效果好于对照组,患者T细胞、NK细胞有所降低,实验组患者生活质量优于对照组,差异明显,(P<0.05)。结论:癌性疼痛患者中利用针灸联合耳穴疗法的效果明显,提高患者生活质量,减少患者疼痛,值得被使用推广。
【关键词】癌性疼痛;针灸;耳穴疗法;效果分析
癌性疼痛是癌症中晚期患者常出现的并发症。国际卫生组织针对疼痛制定了相应的评估标准,数据显示80%的肿瘤晚期患者都会出现疼痛严重,影响患者的身心健康,并降低了患者生活质量【1】。现阶段临床上往往使用三阶药物对患者进行疼痛治疗,但药物镇痛会出现一定的副作用,刺激肿瘤的生长。中医在镇痛方面拥有自身优势,且实施起来方便简洁,副作用小,患者不会对治疗方式产生依赖性。本文研究分析针灸联合耳穴疗法在癌性疼痛患者中的作用效果,现将实验结果整理如下。
1资料与方法
1.1一般资料
选取我院2020年1月至2021年1月癌性疼痛患者80例, 按照随机数字表法将换阵分为实验组与对照组,每组患者40例,实验组患者年龄50-73岁,平均年龄(65.2±3.6)岁,患者疼痛病程3-10个月,平均疼痛病程(5.25±3.26)月,对照组患者年龄53-83岁,平均年龄(67.2±4.6)岁,患者疼痛病程2-10个月,平均疼痛病程(5.25±3.52)月。100例患者中,男性患者62例,女性患者38例,其中肺癌患者30例,乳腺癌患者40例,宫颈癌20例,卵巢癌患者10例。对比两组患者一般资料,无统计学意义,(P>0.05)。
1.2一般方法
两组患者施行药物治疗,实验组患者利用针灸联合耳穴疗法进行治疗,对照组患者仅使用常规三阶梯止疼药。
三阶梯止疼药用药原则:根据患者疼痛情况选择相应的止痛方法,第1阶段:轻度疼痛患者可以使用非阿片类药物缓解疼痛【2】。例如扑热息痛、阿莫西林,布洛芬、吲哚美辛等。第2阶段患者中度疼痛给予阿片类加减,非甾体抗炎药进行治疗。可用可待因、强痛定、弱阿片类药物可能出现天花板效应。第3阶段根据患者实际情况加大药物用量,强阿片类药物可能出现耐受性,吗啡、杜冷丁等。
用药要根据患者实际情况制定相应的用药剂量,以无痛作为原则。
实验组患者利用针灸联合耳穴疗法进行治疗,加上针刺配合耳针疗法在耳边。方案:治疗过程为21天。针灸(全身针灸+电针)7天+耳针疗法14天。肺癌患者:刺激孔最,少府,内关;宫颈癌,卵巢癌,乳腺癌患者刺激:关元,三阴交,阴陵泉;操作方法:利用电针刺激治疗,每天利用一次电针仪,治疗时间长20分钟。患者如发生骨转移,根据肿瘤的原发部位,选择肺,胃,肝,结肠,小肠和骨转移的各自部位进行治疗。手术耳穴手术:取王不留行籽压成丸剂,将其放在耳穴上,用力按压药丸,直到耳朵变红发烫。每次取一颗药丸,每次用一只耳朵按压一次,每2天换成另一只耳朵,替代疗法,每日3次。
1.3观察项目和指标 (1)用VAS疼痛评估患者情况,总分10分,分值越高患者疼痛越明显,根据患者实际情况,进行相应的疼痛评估。(3)两组患者治疗后副作用发生状况。患者治疗前后NK细胞CD3+ 、CD4+、CD8+状况。
1.4统计学方法 采用SPSS18.0软件进行统计学分析,计数资料采用χ2检验,P<0.05说明具有统计学意义。
2.结果
2.1患者疼痛情况
两组患者经过治疗后,疼痛均有所好转,实验组患者疼痛缓解状况优于对照组,差异明显(P<0.05),表1。
表一:患者疼痛情况(x±s,分)
![](data:image/png;base64,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)
2.2患者免疫细胞状况
实验组患者CD3+ 、CD4+、CD8+与对照组之间存在明显差异(P<0.05)。
![](data:image/png;base64,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)
3.讨论
中医针灸联合耳穴疗法具有很好的镇痛效果,能有效的改善患者生活质量。这类方法对于癌痛拥有良好的作用,能有效疏通患者经络,帮助患者平衡阴阳,调和气血【3】。利用针灸刺激穴位可以促进中枢神经系统,从而释放大量的介质及阿片肽。根据不同的癌症及转移部位选择相应的穴位并配合止疼药进行治疗,采用平补平泻手法,可将疼痛率有效降低【4】。本文发现经过针灸联合耳穴治疗,疼痛平均评分为(3.86±1.06)分,患者经护理后CD3+ 、CD4+、CD8+均有所改善,具有统计学意义(P<0.05)。综上所述,癌性疼痛患者中利用针灸联合耳穴疗法的效果明显,提高患者生活质量,减少患者疼痛,值得被使用推广。
参考文献:
[1]杨康栋,赵晓勤.针刺联合运动疗法治疗原发性高血压疗效观察[J].山西中医,2017,33(10):26-27,42
[2]童亚运,王晓燕,黄春娇,等.耳穴压豆配合中药穴位贴敷应用于癌痛患者的疗效研究[J].特别健康,2020,(21):17.
[3]凡国华,宋亚男,孙静云,等.揿针耳穴联合腧穴治疗肺癌化疗患者睡眠障碍的疗效观察[J].护士进修杂志,2020,35(19):1803-1807.
[4]吴迁.耳穴疗法联合针灸对老年轻度高血压的治疗效果[J].健康大视野,2020,(8):113,115.